<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03617731</url>
  </required_header>
  <id_info>
    <org_study_id>GMMG HD7</org_study_id>
    <nct_id>NCT03617731</nct_id>
  </id_info>
  <brief_title>Trial on the Effect of Isatuximab to Lenaliodomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)</brief_title>
  <official_title>A Randomized Phase III Trial Assessing the Benefit of the Addition of Isatuximab to Lenalidomide / Bortezomib / Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Heidelberg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Heidelberg Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial in patients with newly diagnosed myeloma to evaluate the effect of isatuximab in
      induction therapy with lenalidomide/bortezomib/dexamethasone (RVd) and in lenalidomide
      maintenance treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multicentre, randomised, parallel group, open, phase III clinical trial, for
      patients with confirmed diagnosis of untreated multiple myeloma requiring systemic therapy.

      Investigational Medicinal Products: Isatuximab, Lenalidomide

        1. Randomization: Patients are randomized in one of 2 study arms (IA or IB) before
           induction therapy. Patients randomized in arm IA will receive 3 cycles RVd (Bortezomib
           (Velcade®), Lenalidomide (Revlimid®, each cycle is 42 days), Dexamethasone). Patients in
           arm IB will additionally receive the monoclonal antibody Isatuximab in the 3 cycles RVd.
           After induction therapy patients undergo intensifying therapy according to GMMG standard
           (usually mobilization therapy followed by stem cell collection and autologous stem cell
           transplantation).

        2. Randomization: Before maintenance treatment patients are randomized in one of 2 study
           arms (IIA and IIB): Patients in arm IIA receive Lenalidomide maintenance therapy for
           three years, patients in arm IIB receive additional Isatuximab.

      There are two primary objectives:

        1. to compare the induction regimen (IA vs IB) regarding minimal residual disease (MRD)
           negativity after induction (assessed by flow cytometry; sensitivity at least 1e-5)

        2. to compare the maintenance strategies (arms IIA vs IIB) regarding progression-free
           survival (PFS), defined as time from 2nd randomization (prior to maintenance therapy) to
           progression or death from any cause whichever occurs first.

      The duration of the trial for each patients is expected to be 45-48 months (induction and
      intensification treatment: 6-9 months, 3 months rest between intensification and start of
      maintenance phase 36 months).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 18, 2018</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 x 2 arms, 1. randomization before induction therapy (arm IA and IB), 2. randomization before maintenance therapy (arm IIA and IIB)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRD negativity after induction Treatment (comparison of arms IA and IB)</measure>
    <time_frame>18 weeks after start of study treatment</time_frame>
    <description>Detection of minimal residual disease by flow cytometry (sensitivity at least 1e-5)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) after second randomization (arms IIA and IIB)</measure>
    <time_frame>time from 2. randomization to progression or death from any cause whichever comes first, censored after three years of maintenance therapy</time_frame>
    <description>Response Evaluation by IMWG criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to compare the four treatment arms (IA-IIA, IA-IIB, IB-IIA, IB-IIB) regarding Progression free survival (PFS)</measure>
    <time_frame>time from 1. randomization (study inclusion) to progression or death whichever comes first (assessed up to 79 months)</time_frame>
    <description>Response evaluation by IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>to compare all 4 treatment arms (IA-IIA, IA-IIB, IB-IIA, IB-IIB) regarding overall survival (OS) from time of 1.randomization</measure>
    <time_frame>time from randomisation to time of death from any cause (assessed up to 79 months)</time_frame>
    <description>survival status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival from second randomization</measure>
    <time_frame>time from 2. randomization to time of death from any cause (assessed up to 75 months)</time_frame>
    <description>survival status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) rates after induction therapy</measure>
    <time_frame>After induction treatment (18 weeks after start of treatment)</time_frame>
    <description>Response Evaluation by IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) after high dose therapy</measure>
    <time_frame>After high dose therapy (9 or 12 months after start of therapy)</time_frame>
    <description>Response Evaluation by IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response (CR) during/after maintenance therapy</measure>
    <time_frame>During/after maintenance therapy (6 months after start of therapy up to 36 months of maintenance therapy)</time_frame>
    <description>Response Evaluation by IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD negativity after high dose therapy</measure>
    <time_frame>After high dose therapy (9 or 12 months after start of therapy)</time_frame>
    <description>Detection of minimal residual disease by flow cytometry (sensitivity at least 1e-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRD negativity during and after maintenance therapy</measure>
    <time_frame>up to 36 months after start of maintenance therapy</time_frame>
    <description>Detection of minimal residual disease by flow cytometry (sensitivity at least 1e-5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response to treatment during the trial</measure>
    <time_frame>response assessment after 3 months, 4,5 months, 5,5 months, 9 months (if applicable: 3 months later after 2. high dose therapy) subsequently every 3 months during maintenance treatment, up to 48 months after start of study treatment</time_frame>
    <description>Response evaluation by IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS 2 (PFS after next line of therapy) from 2. randomization</measure>
    <time_frame>time from 2. randomization to time of overall end of trial (up to 75 months)</time_frame>
    <description>Response evaluation by IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity during induction and maintenance with respect to adverse events of CTC grade &gt;3 (and specific adverse events of CTC grade &gt; 2 as defined in the protocol and serious adverse events</measure>
    <time_frame>: from first administration of study drug until 30 days after last administration of study drug or any drug of the study treatment or upon start of a new subsequent chemotherapy, whichever occurs first</time_frame>
    <description>toxicity according CTCAE Version v5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment</measure>
    <time_frame>assessed at baseline, after ca. 4.5 months, 9 months, (additionally after 12 months,if a second high dose therapy is administered) after 12 months of maintenance and at end of study (up to 50 months)</time_frame>
    <description>EORTC (European Organization of Research and Treatment of Cancer) -QLQC30 Questionnaire to assess the quality of life of cancer patients. Impairment of daily life is asked in 4 scales from &quot;not at all&quot; (best) to &quot;very much&quot; (worst scale), EORTC-QLQMY20 questionnaire to assess health-related quality of life in patients with multiple myeloma with 4 scales from &quot;not at all (best scale) to &quot;very much&quot; (worst scale); EQ(EuroQol Group)-5D-5L Health questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. Additionally a visual analogue scale from 100 (best) to 0 (worst scale) is used to assess the quality of health questionnaires.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmakokinetic analyses of Isatuximab in induction treatment of patients in Arm IB (selected sites only)</measure>
    <time_frame>Up to 18 weeks in induction treatment (C1: D1, before infusion, at end of infusion, 1 h after infusion, C1 D8,15,22,29 before infusion; C2 and 3:D1 before infusion</time_frame>
    <description>Determination of serum concentration of isatuximab at different timepoints before, during and after isatuximab infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmakokinetic analyses of Isatuximab in maintenance treatment of patients in Arm IIB (selected sites only)</measure>
    <time_frame>Up to 9 months (C1: D1, before infusion, at end of infusion, 1 h after infusion, C1 D8,15,22 before infusion, C2 -9, D1: before infusion</time_frame>
    <description>Determination of serum concentration of isatuximab at different timepoints</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">662</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>IA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in arm IA are treated with 3 cycles RVd (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32; dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in arm IB are treated with 3 cycles RVd + Isatuximab (lenalidomide 25 mg/d p.o. d1 - 14 and d22 - 35; bortezomib 1.3 mg/m2 s.c. d1, 4, 8, 11, 22, 25, 29, 32;dexamethasone p.o. 20 mg/d d1-2, 4-5, 8-9, 11-12, 15, 22-23, 25-26, 29-30, 32-33).Isatuximab (10 mg/kg i.v. C1: d 1, 8, 15, 22, 29; C2-3: d 1, 15, 29).Treatment repeats every 42 days (d43 = cycle 2 d1). Standard intensification: For all patients, stem cells are mobilized by GMMG Standard protocols (CAD: cyclophosphamide, doxorubicin, dexamethasone) and G-CSF. At least 7.5x106 CD34+ cells/kg body weight are harvested. High dose treatment (melphalan 200mg/m², HDT) followed by autologous stem cell transplantation (ASCT) is started 4 - 6 weeks after CAD. For patients not in CR after HDT1, a second HDT is performed within 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IIA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) repeated every 28d. Maintenance treatment is planned for up to 36 months or until progression if progression occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>maintenance treatment with Lenalidomide 10mg/d (increased to 15mg/d after 3 months) + Isatuximab (10 mg/kg; C1: d1, 8, 15, 22; C2-C3: d1 + 15; C4-39:d1, repeated every 28d). Within the trial, maintenance treatment is planned for up to 36 months or until progression if progression occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>25 mg per os on day 1-14 and d22-35 in induction cycle 1-3 (Arms IA and IB) 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-39 (Arms IIA and IIB)</description>
    <arm_group_label>IA</arm_group_label>
    <arm_group_label>IB</arm_group_label>
    <arm_group_label>IIA</arm_group_label>
    <arm_group_label>IIB</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib</intervention_name>
    <description>all arms: 1,3 mg/m^2 subcutaneous on day 1, 4, 8, 11, 22, 25, 29 32 in 3 induction cycles</description>
    <arm_group_label>IA</arm_group_label>
    <arm_group_label>IB</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 and 22,23 and 25,26 and 29,30 and 32,33 in induction cycles 1-3 (Arms IA and IB). Maintenance cycle 1 on day 1, 8, 15, 22 Dexamethasone 20 mg/d per os (Arm IIA). In Arm IIB Dexamethasone 20 mg i.v. on days of Isatuximab infusion in the first maintenance cycle (d 1, 8, 15, 22), dexamethasone will be administered intravenously as part of the premedication. If an isatuximab dose is skipped or discontinued dexamethasone should be administered orally.</description>
    <arm_group_label>IA</arm_group_label>
    <arm_group_label>IB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isatuximab</intervention_name>
    <description>10 mg/kg in the vein( i.v) on day 1,8,15, 22, 29 in induction cycle 1 on day 1, 15 and 29 in induction cycle 2 and 3 (Arm IB). 10 mg/kg i.v. on day 1,8, 15 and 22 in maintenance cycle 1, 10 mg/kg i.v. on day 1 and 15 in maintenance cycle 2 and 3, 10 mg/kg i.v. on day 1 in maintenance cycle 4 - 39 (Arm IIB)</description>
    <arm_group_label>IB</arm_group_label>
    <arm_group_label>IIB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of untreated multiple myeloma requiring systemic therapy
             (diagnostic criteria (IMWG updated criteria (2014)1) see appendix IA. For some
             patients systemic therapy may be required though these diagnostic criteria are not
             fulfilled. In this case the GMMG study office has to be consulted prior to inclusion.)

          2. Patient is eligible for high dose therapy and autologous stem cell transplantation.

          3. Measurable disease, defined as any quantifiable monoclonal protein value, defined by
             at least one of the following three measurements:2

               -  Serum M-protein ≥ 10g/l (for IgA ≥ 5g/l)

               -  Urine light-chain (M-protein) of ≥ 200 mg/24 hours

               -  Serum FLC assay: involved FLC level ≥ 10 mg/dl provided sFLC ratio is abnormal

          4. Age 18 - 70 years inclusive

          5. WHO performance status 0-2

          6. Negative pregnancy test at inclusion (females of childbearing potential)

          7. All patients must agree on the requirements regarding the lenalidomide pregnancy
             prevention plan described in section 6. For all men and females of childbearing
             potential: patients must be willing and capable to use adequate contraception during
             the complete therapy.

          8. All patients must

               -  agree to abstain from donating blood while taking lenalidomide and for 28 days
                  following discontinuation of lenalidomide therapy

               -  agree not to share study drug lenalidomide with another person and to return all
                  unused study drug to the investigator or pharmacist

          9. Ability of patient to understand character and individual consequences of the clinical
             trial

         10. Provide written informed consent (must be available before enrolment in the trial)

        Exclusion Criteria

          1. Patient has known hypersensitivity (or contraindication) to dexamethasone, sucrose
             histidine (as base and hydrochloride salt), boron, mannitol, and polysorbate 80 or any
             of the components of study therapy that are not amenable to premedication with
             steroids or H2 blockers that would prohibit further treatment with these agents.

          2. Systemic AL amyloidosis (except for AL amyloidosis of the skin or the bone marrow)

          3. Plasma cell leukemia

          4. Previous chemotherapy or radiotherapy during the past 5 years except local
             radiotherapy in case of local myeloma progression. (Note: patients may have received a
             cumulative dose of up to 160 mg of dexamethasone or equivalent as emergency therapy.)
             Previous therapy due to smouldering myeloma may be acceptable. In this case the GMMG
             study office has to be consulted prior to inclusion

          5. Severe cardiac dysfunction (NYHA classification III-IV), ejection fraction &lt; 40%

          6. Significant hepatic dysfunction (ASAT and/or ALAT ≥ 3 times normal level and/or serum
             bilirubin ≥ 1.5 times normal level if not due to hereditary abnormalities as Gilbert's
             disease), unless related to myeloma.

          7. Patients with active or history of hepatitis B or C

          8. HIV positivity

          9. Patients with active, uncontrolled infections

         10. Patients with severe renal insufficiency (Creatinine Clearance &lt; 30ml/min)

         11. Patients with peripheral neuropathy or neuropathic pain, CTC grade 2 or higher (as
             defined by the NCI Common Terminology Criteria for Adverse Events (NCI CTCAE) Version
             5.0)

         12. Patients with a history of active malignancy during the past 5 years with the
             exception of following malignancies after curative therapy: basal cell carcinoma of
             the skin, squamous cell skin carcinoma, stage 0 cervical carcinoma or any in situ
             malignancy

         13. Patients with acute diffuse infiltrative pulmonary and/or pericardial disease

         14. Autoimmune hemolytic anemia with positive Coombs test or immune thrombocytopenia

         15. Platelet count &lt; 75 x 109/l

         16. Haemoglobin &lt; 8.0 g/dl, unless related to myeloma

         17. Absolute neutrophil count (ANC) &lt; 1.0 x 109/l (the use of colony stimulating factors
             within 14 days before the test is not allowed)

         18. Corrected serum calcium &gt; 14 mg/dl (&gt; 3.5 mmol/l)

         19. Unable or unwilling to undergo thromboprophylaxis

         20. Pregnancy and lactation

         21. Participation in other clinical trials. This does not include long-term follow-up
             periods without active drug treatment of previous studies during the last 6 months.

         22. Prisoners or subjects who are legally institutionalized, or those unwilling or unable
             to comply with scheduled visits, drug administration plan, laboratory tests, other
             study procedures, and study restrictions.

        No patients will be allowed to enrol in this trial more than once.

        -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hartmut Goldschmidt, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Med. Klinik V, University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>GMMG Study Office</last_name>
    <phone>0049-6221-568198</phone>
    <email>studiensekretariat.gmmg@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Uta Bertsch, Dr.</last_name>
    <phone>0049-6221-568015</phone>
    <email>uta.bertsch@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen, Klinik für Hämatologie, Onkologie, Hämostaseologie und Stammzelltransplantation</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deniz Gezer, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studienzentrum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>63739</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martine Klausmann, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Bad Saarow, Klinik für Hämatologie, Onkologie und Palliativmedizin</name>
      <address>
        <city>Bad Saarow</city>
        <zip>15526</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Schöndube, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Charité, Campus Benjamin Franklin , III. Medizinische Abteilung (Hämatologie/Onkologie)</name>
      <address>
        <city>Berlin</city>
        <zip>12200</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Igor Wolfgang Blau, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln, Klinik für Hämatologie und Onkologie</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maike de Wit, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum, Klinik für Hämatologie, Onkologie und Immunologie</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Fuhrmann, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Studiengesellschaft Onkologie Bielefeld GbR</name>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hendrik Riesenberg, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld, Klinik für Hämatologie, Onkologie und Palliativmedizin</name>
      <address>
        <city>Bielefeld</city>
        <zip>D-33604</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Görner, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik, Knappschaftskrankenhaus</name>
      <address>
        <city>Bochum</city>
        <zip>D-44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Schroers, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik III, Schwerpunkt Onkologie, Hämatologie und Rheumatologie</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Holderried, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johanniter Krankenhaus Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yon-Dschun Ko, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zentrum für ambulante Hämatologie und Onkologie (ZAHO)</name>
      <address>
        <city>Bonn</city>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Verbeek, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig, Med. Klinik III, Hämatologie und Onkologie</name>
      <address>
        <city>Braunschweig</city>
        <zip>38114</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arne Trummer, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Chemnitz GmbH, Innere Medizin III</name>
      <address>
        <city>Chemnitz</city>
        <zip>D-09116</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Hänel, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Carl-Thiem-Klinikum Cottbus gGmbH, II. Medizinische Klinik</name>
      <address>
        <city>Cottbus</city>
        <zip>03048</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Schmidt-Hieber, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologisches Studienzentrum Darmstadt</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerrit Dingeldein</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Darmstadt, Med. Klinik V, Hämatologie/Onkologie</name>
      <address>
        <city>Darmstadt</city>
        <zip>D-64283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helga Bernhardt, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus Dresden, an der Technischen Universität Dresden, Medizinische Klinik und Poliklinik I</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolin Trautmann-Grill, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HELIOS St. Johannes Klinik, Akademisches Krankenhaus der Heinrich-Heine-Universität Düsseldorf</name>
      <address>
        <city>Duisburg</city>
        <zip>47166</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Heinsch, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Düsseldorf GmbH, Klinik für Onkologie, Hämatologie und Palliativmedizin</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40479</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maika Klaiber-Hakimi, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Klinik für Hämatologie,Onkologie und Klin. Immunologie</name>
      <address>
        <city>Düsseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Fenk, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Ferstl, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Antonius-Hospital Eschweiler, Klinik für Hämatologie / Onkologie</name>
      <address>
        <city>Eschweiler</city>
        <zip>52249</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Staib, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik für Hämatologie</name>
      <address>
        <city>Essen</city>
        <zip>D-45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Dürig, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ev. Krankenhaus Essen-Werden gGmbH, Zentrum für Innere Medizin, Klinik für Hämatologie, Onkologie und Stammzelltransplantation</name>
      <address>
        <city>Essen</city>
        <zip>D-45239</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Reimer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Prof. Dr. Michael Kiehl und Dipl. Med. Wolfgang Stein</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kiehl, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Frankfurt (Oder) GmbH</name>
      <address>
        <city>Frankfurt (Oder)</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olaf Hopfer, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centrum für Hämatologie und Onkologie Bethanien</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Knauf, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus, Med. Klinik I</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claus Bolling, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Nordwest, Institut für Klinisch-Onkologische Forschung</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60488</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eckhart Weidmann, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Goethe-Universität Medizinische Klinik II</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Martin, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Fulda, Klinisches Studienzentrum GmbH</name>
      <address>
        <city>Fulda</city>
        <zip>36043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe Kostrewa, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik der Justus-Liebig-Universität, Medizinische Klinik IV</name>
      <address>
        <city>Gießen</city>
        <zip>35385</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Rummel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Katholisches Karl-Leisner-Klinikum gGmbH, Wilhelm-Anton-Hospital Goch, Klinik für Hämatologie - Onkologie</name>
      <address>
        <city>Goch</city>
        <zip>47574</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Volker Runde, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kath. Krankenhaus Hagen gGmbH, Abt. Hämatologie/Onkologie</name>
      <address>
        <city>Hagen</city>
        <zip>D-58095</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Walter Lindemann, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Hamburg St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Salwender, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf, Zentrum für Onkologie, Studienzentrale der II. Medizinischen Klinik</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aneta Schieferdecker, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Hamburg Altona, II. Med. Klinik</name>
      <address>
        <city>Hamburg</city>
        <zip>D-22763</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Salwender, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Immunologisch-onkologisches MVZ am Siloah Krankenhaus</name>
      <address>
        <city>Hannover</city>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter von Wussow, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>KRH Klinikum Siloah, Klinik für Hämatologie und Onkologie</name>
      <address>
        <city>Hannover</city>
        <zip>30459</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Müller, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Debatin, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus St. Vincentius der evangelischen Stadtmission Heidelberg, Abt. Hämatologie, Onkologie, Rheumatologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerlinde Egerer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Heidelberg, Med. Klinik V</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GMMG Study Office</last_name>
      <email>studiensekretariat.gmmg@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Hartmut Goldschmidt, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SLK Kliniken Heilbronn, Med. Klinik III</name>
      <address>
        <city>Heilbronn</city>
        <zip>D-74078</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Uwe Martens, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marien Hospital Herne</name>
      <address>
        <city>Herne</city>
        <zip>44625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beate Schultheis, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes, Innere Medizin I</name>
      <address>
        <city>Homburg (Saar)</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominic Kaddu-Mulindwa, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westpfalz-Klinikum GmbH, Klinik für Innere Medizin I</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Held, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Städtisches Klinikum Karlsruhe</name>
      <address>
        <city>Karlsruhe</city>
        <zip>76133</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Ringhoffer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxisklinik für Hämatologie und Onkologie</name>
      <address>
        <city>Koblenz</city>
        <zip>D-56068</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Thomalla, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln, Klinik I für Innere Medizin</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christof Scheid, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie am Caritas Krankenhaus</name>
      <address>
        <city>Lebach</city>
        <zip>66822</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Kremers, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig AöR, Medizinische Klinik und Poliklinik I-Hämatologie und Zelltherapie, Internistische Onkologie, Hämostaseologie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfram Pönisch, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Med. Klinik A, Klinikum der Stadt Ludwigshafen am Rhein gGmbH</name>
      <address>
        <city>Ludwigshafen am Rhein</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Hoffmann, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, III. Med. Klinik</name>
      <address>
        <city>Mainz</city>
        <zip>D-55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Munder, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>III. Medizinische Klinik Hämatologie und Internistische Onkologie</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Klein, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mannheimer Onkologie Praxis</name>
      <address>
        <city>Mannheim</city>
        <zip>D-68161</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manfred Hensel, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philipps-Universität Marburg, Hämatologie/Onkologie/Immunologie</name>
      <address>
        <city>Marburg</city>
        <zip>35032</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Mann, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mühlenkreiskliniken (AöR) Johannes Wesling Klinikum Minden, Hämatologie/Onkologie, Hämostaseologie und Palliativmedizin</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Joachim Tischler, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Maria Hilf GmbH, Franziskuskrankenhaus, Med. Klinik I</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>D-41063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ullrich Graeven, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster, Med. Klinik A</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cyrus Khandanpour, PD Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Osnabrück GmbH</name>
      <address>
        <city>Osnabrück</city>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Kropff, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brüderkrankenhaus St. Josef Paderborn, Klinik für Hämatologie und Onkologie</name>
      <address>
        <city>Paderborn</city>
        <zip>33098</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tobias Gaska, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Krankenhaus Barmherzige Brüder, Klinik für Onkologie und Hämatologie</name>
      <address>
        <city>Regensburg</city>
        <zip>93049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Heilmeier, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie, Onkologisches Zentrum</name>
      <address>
        <city>Saarlouis</city>
        <zip>66740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Kremers, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Schwäbisch Hall gGmbH, Innere Medizin III</name>
      <address>
        <city>Schwäbisch Hall</city>
        <zip>74523</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Geer, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ZAHO-Zentrum für ambulante Hämatologie und Onkologie, Standort Siegburg</name>
      <address>
        <city>Siegburg</city>
        <zip>D-53721</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefan Fronhoffs, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Speyer</name>
      <address>
        <city>Speyer</city>
        <zip>D-67346</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Behringer, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Stuttgart Cancer Center, Tumorzentrum Eva Mayr-Stihl</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia Riechel, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Mutterhaus der Borromäerinnen gGmbH</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rolf Mahlberg, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Tübingen, Med. Klinik und Poliklinik, Abt. II</name>
      <address>
        <city>Tübingen</city>
        <zip>D-72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Britta Besemer, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bundeswehrkrankenhaus Ulm, Abteilung Innere Medizin - Hämatologie und internistische Onkologie</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armin Riecke, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum, Innere Medizin II</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Graf La Rosée, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rems-Murr-Kliniken gGmbH</name>
      <address>
        <city>Winnenden</city>
        <zip>71364</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Schaich, Prof. Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 24, 2018</study_first_submitted>
  <study_first_submitted_qc>July 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2018</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Heidelberg Medical Center</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Hartmut Goldschmidt</investigator_full_name>
    <investigator_title>Head of Division of Multiple Myeloma</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

